Opendata, web and dolomites

H2020MM04 SIGNED

DC-based immunotherapy to treat Malignant Mesothelioma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 H2020MM04 project word cloud

Explore the words cloud of the H2020MM04 project. It provides you a very rough idea of what is the project "H2020MM04" about.

twice    therapeutic    cisplatin    despite    illness    exposed    iarc    international    pulsed    occupational    cells    massively    care    risk    allogeneic    fatal    treatment    fda    cell    adverse    first    rotterdam    netherlands    mc    resistant    incidence    environment    16    survival    approval    ema    chemotherapy    curative    immunotherapy    time    standard    2065    ini    actions    12    13    inhalation    months    fibres    poor    06    autologous    24    considerably    2010    treatments    registration    orphan    dendritic    2012    tremendously    malignant    disease    personalised    immuno    combination    extremely    deaths    designation    reported    extensive    aggressive    pemetrexed    therapy    mm    death    health    consumers    last    workers    lysate    events    prospects    history    tumour    carcinogens    banned    erasmus    granted    date    trial    median    quantities    pulmonary    clinical    limited    asbestos    consisting    union    january    mesothelioma    treat    millions    1229    market    resolution    protecting    threats    diseases    scientific    prolonged    abolishing    signs    2014   

Project "H2020MM04" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.denimstudy.eu/
 Total cost 5˙782˙965 €
 EC max contribution 5˙782˙965 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 2˙375˙146.00
2    UNIVERSITA POLITECNICA DELLE MARCHE IT (ANCONA) participant 669˙452.00
3    STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS NL (AMSTERDAM) participant 669˙451.00
4    UNIVERSITY OF LEICESTER UK (LEICESTER) participant 669˙215.00
5    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 668˙874.00
6    CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE FR (LILLE) participant 659˙822.00
7    AMPHERA BV NL (DEN BOSCH) participant 48˙000.00
8    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 23˙000.00

Map

 Project objective

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millions of workers & consumers in the EU were, and still are, for many years exposed to asbestos fibres, despite all measures.

Inhalation of even very low quantities of asbestos fibres tremendously increases the risk of developing Malignant Mesothelioma (MM). The IARC reported 8.100 MM deaths in 2010 in the EU. Despite all EU actions, MM incidence is still increasing. MM is a highly fatal disease with a poor median survival time from first signs of illness to death around 12 months despite aggressive treatments. To date there is no curative therapy for MM. MM is considered as an extremely therapy-resistant disease. Chemotherapy consisting of a combination of pemetrexed and cisplatin is considered standard of care with a median survival increase of 3 months (9-12 months).

The department of pulmonary diseases of the Erasmus MC, Rotterdam, The Netherlands, in collaboration with international partners, have developed a promising personalised immunotherapy for MM with very limited adverse effects. The first clinical results show a considerably prolonged average survival with limited adverse events (24 months, twice as long).

The EMA and the FDA granted this therapy Orphan Designation: autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma (EU: 16 January 2014 - EU/3/13/1229; FDA – US: 06 May 2014).

The objective for the project is to deliver the scientific & registration package for market approval by the EMA of a novel immuno therapeutic approach to treat MM. This includes the execution of a phase II/III clinical trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "H2020MM04" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "H2020MM04" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More